MHRAsafety guidance72% confidence
Guidance: AI Airlock Sandbox Phase 2 Programme Report
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to pridopidine.
Regulatory Analysis
The MHRA’s AI Airlock second phase ran between April 2025 and May 2026. This report does not constitute formal MHRA guidance.
Supporting Context
- Therapeutic area
- Neurology · ALS
- Sub-indication
- General
Related signal: Pridopidine Phase 3 Trial Initiated for ALS Efficacy and Safety Evaluation
Source
FDA document
View source